|
Patent landscape, scope, and claims: |
United States Patent 7,838,552: Scope, Claims, and Patent Landscape Analysis
What is the scope and content of Patent 7,838,552?
Patent 7,838,552, filed by Eli Lilly and granted in November 2010, covers compounds and methods related to BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitors. The patent primarily aims to protect specific chemical entities intended to inhibit BACE activity, which is involved in amyloid-beta production linked to Alzheimer’s disease.
The patent claims cover:
- Chemical Compounds: Structures described generally as acyl, aryl, and heteroaryl derivatives with substitutions tailored for BACE inhibition.
- Methods of Use: Pharmaceutical methods for treating BACE-related cognitive decline, particularly Alzheimer’s disease.
- Manufacturing and Formulation: Techniques for synthesizing the compounds and formulating them into therapeutic compositions.
Key features include:
- Specific substituents on the core scaffold designed to enhance potency and selectivity.
- Use of certain carbamate, amide, or sulfonamide linkers.
- Pharmaceutical formulations suitable for oral administration or injection.
How broad are the claims?
The patent claims are structured into multiple groups, with the broadest claims covering:
- Any compound with the core structure represented as a generalized chemical formula (see below).
- Substituted derivatives with specific heteroatoms and functional groups.
- Methods of inhibiting BACE activity using these compounds.
- Methods of treating Alzheimer’s disease by administering a compound falling within the claimed scope.
Example of the core chemical claim:
"A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3,... are defined as various functional groups."
The claims aim to encompass a wide array of chemical variations within the core structure, effectively covering numerous analogs, including future derivatives designed around the same scaffold.
How does the patent landscape look globally?
US Patent Landscape:
- The patent is part of a broader portfolio targeting BACE inhibitors, including US, Europe, and Japan patents.
- The US patent family includes related applications filed in 2004-2006, with continuation and divisional applications extending coverage.
- Other assignees, such as Merck and AstraZeneca, hold similar patents targeting chemistries and methods for BACE inhibition, leading to potential patent thickets.
Key related patents:
| Patent Number |
Assignee |
Issue Date |
Scope Summary |
| EP 1,779,481 |
Eli Lilly |
2010 |
European counterpart covering similar compounds and methods |
| US 8,290,128 |
Merck & Co |
2012 |
BACE inhibitors with different scaffold chemistry |
| WO 2012/063747 |
AstraZeneca |
2012 |
Similar chemical series targeting BACE |
Patent expiry:
- The patent filing date is May 21, 2008.
- Patent term is 20 years from filing, expiring around 2028, assuming maintenance fees are paid.
Infringement and freedom-to-operate considerations
- The broad claims covering general chemical structures can pose barriers for generic development.
- Narrower patents surrounding specific derivatives or formulations could be designed to circumvent the patent.
- Companies developing BACE inhibitors must consider potential patent thickets and overlapping claims, especially in Europe and Japan.
Competitive landscape
- Eli Lilly’s portfolio for BACE inhibition is among the most extensive, with multiple patents covering distinct scaffold chemistries.
- Other pharmaceutical companies have filed related applications, but few have achieved regulatory approval for BACE inhibitors.
- The landscape is characterized by patenting early-stage compounds and methods, which could impact licensing and development strategies.
Key technical insights
- The chemical claims focus on core scaffolds with various substituents to optimize binding affinity.
- The patent emphasizes specific stereochemistry, functional groups, and linkers to achieve activity and selectivity.
- Examples include compounds with varied heteroaryl groups, carbamates, and amides, tailored for crossing the blood-brain barrier and reducing amyloid-beta levels.
Conclusion
Patent 7,838,552 covers a comprehensive chemical class of BACE inhibitors with broad claims that extend to many derivatives. It is part of an active patent landscape targeting Alzheimer’s disease therapeutics, with overlapping claims from other major pharmaceutical players. The patent’s scope includes chemical structures, methods of treatment, and formulations, providing robust coverage until approximately 2028.
Key Takeaways
- The patent protects a wide array of chemical compounds designed to inhibit BACE and treat Alzheimer’s disease.
- Claim breadth covers core scaffolds, substituents, and methods, complicating generic entry.
- The patent landscape includes filings by Eli Lilly and competitors, with potential patent thickets across major jurisdictions.
- Development strategies should consider narrow patent restrictions and the timeline until patent expiration.
- The scope remains relevant for companies engaged in Alzheimer’s drug R&D, especially in BACE inhibitor development.
FAQs
1. What is the primary therapeutic target of Patent 7,838,552?
It targets BACE enzymes involved in amyloid-beta production, relevant to Alzheimer’s disease.
2. How broad are the chemical claims within the patent?
They cover general chemical structures with various substituents, effectively encompassing a wide range of derivatives.
3. Are there similar patents owned by other companies?
Yes, companies like Merck and AstraZeneca hold related patents on BACE inhibitors with different scaffolds.
4. When does the patent expire?
Patents filed in 2008 generally expire around 2028, assuming maintenance fees are paid.
5. What are the implications for generic drug development?
The broad claims and overlapping patents pose barriers, requiring careful freedom-to-operate analysis.
References
- Eli Lilly and Company. (2008). U.S. Patent No. 7,838,552.
- European Patent Office. (2010). EP 1,779,481.
- Merck & Co. Inc. (2012). U.S. Patent No. 8,290,128.
- World Intellectual Property Organization. (2012). WO 2012/063747.
More… ↓
⤷ Start Trial
|
